Clearside Biomedical: Q2 Earnings Insights

Shares of Clearside Biomedical CLSD were flat in after-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share were up 15.38% over the past year to ($0.11), which beat the estimate of ($0.12).

Revenue of $780,000 up by 120.34% year over year, which beat the estimate of $690,000.

Looking Ahead

Clearside Biomedical hasn't issued any earnings guidance for the time being.

Clearside Biomedical hasn't issued any revenue guidance for the time being.

Conference Call Details

Date: Aug 10, 2021

Time: 04:30 PM

ET Webcast URL:

Recent Stock Performance

52-week high: $7.29

Company's 52-week low was at $1.25

Price action over last quarter: Up 107.56%

Company Profile

Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye. The product candidates of the company focus on a disease affecting the retina and aim to restore or improve visual function primarily by reducing the macular edema associated with several diseases affecting vision.

Market News and Data brought to you by Benzinga APIs
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsBZI-Recaps
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!